This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The aim was to evaluate the cost-effectiveness of smoking cessation therapies, with a hypothetical test for a single gene polymorphism (dopamine receptor D2, DRD2, gene), which predicts treatment response. The therapies, for smokers with European ancestry seeking help to quit, were nicotine replacement therapy (NRT), bupropion, their combination, or standard care. There were two control groups, one of which received brief advice, and the other individual counselling.
Interventions
The DRD2 gene Taq1A polymorphism had been shown to identify populations with different response rates to NRT and bupropion. Ten different strategies were considered for each control group. Four strategies did not involve DRD2 testing and all the genotypes were treated similarly. In the remaining six strategies, the DRD2 test was used to allocate treatment according to the patient's genotype; CC (A2A2) was compared with CT (A2A1) and TT (A1A1).
Location/setting
UK/primary care.
Methods

Analytical approach:
A model that combined the 12 month cessation rates, relapse rates, lifetime QALYs gained by lifetime cessation, and costs was developed and analysed using Bayesian synthesis methods in WinBUGs. The time horizon was lifetime and the authors reported that a National Health Service (NHS) perspective was used.
Effectiveness data:
The effectiveness parameters came from a non-systematic literature review, and relied heavily on a previous economic model (Woolacott, et al. 2002 , see 'Other Publications of Related Interest' below for bibliographic details), which included a systematic review of clinical effectiveness and three studies that investigated the effect of genotype on cessation rates. The main effectiveness estimates included the 12 month cessation rates of the different strategies, as well as their modifications according to different genetic sub-populations, and relapse rates.
Monetary benefit and utility valuations:
Quality-adjusted life-years (QALYs) gained from lifetime smoking cessation were extracted from Woolacott, et al. 2002. 
